Member Info for miningforgold

Regardless .. this is exporation, not AI not Crypto not Bitcoin Treasury .. so likely fall on this epic news !!

lol

EXCEPTIONAL

· Assay results received for holes CNG25-DD010 - DD014 with significant intervals including;

Ø DD013: 5m @ 3.04% Cu and 322.4 g/t Ag from 37m, within a broader zone of

§ 13.9m @ 1.74% Cu and 153.4 g/t Ag from 26.1m

Ø DD012: 3m @ 3.43% Cu and 164.7 g/t Ag from 24m, within a broader zone of

§ 20m @ 32.1g/t Ag from 7m (copper and silver leached in surface oxide zone)

Ø DD010: 19m @ 30.5g/t Ag from 6m, including

§ 8.8m @ 58g/t Ag from 10.2m (copper and silver leached in surface oxide zone)

· CNG25-DD012 confirms mineralisation up to 500m south of the Mostaza mine

· Exploration holes DD010, DD012 and DD014 intersected broad zones of anomalous silver in silicified leached rock near surface stongly indicative of the potential for high-grade sulphide Cu-Ag mineralisation at depth

· Phase III drilling is planned to target beneath the broad leached mineralisation zones

· Pole-dipole induced polarisation (PDIP), gradient, and audio frequency magneto-telluric (AMT) geophysical surveys are underway in advance of Phase III drilling

· Further assays pending on holes CNG25 DD015 - DD025

· GSC holds option to own 100% of the Cerro Negro project including the Mostaza mine

· Prospect located at low elevation with excellent access to infrastructure and mining services

Sam Garrett, Chief Executive Officer of Great Southern Copper, said:

"The exciting results at Mostaza continue with drilling below the historical Mostaza mine intersecting further outstanding high-grade Cu-Ag mineralisation that remains open along strike and at depth.

"In addition, our exploration drilling, designed to test for mineralisation beyond the historical pit, also intersected significant mineralisation over 500 metres south of the mine. Holes DD010, 012 and 014 have intersected broad zones of anomalous silver hosted in highly leached rocks near surface, which we believe represent the possible oxidised tops of sulphide-rich, high-grade Cu-Ag mineralised lens material at depth.

"Our very exciting drill results, together with the recently started geophysical surveys, preliminary petrography, and metallurgical test work, are setting the stage for an exciting Phase III drill programme.

"We look forward to sharing more exciting results as they become available."

It's either £0.00 or multi multi multi multi bag potential

I love the risk /reward ratio here personally and comfortable with losing it all (though I don't think I will)

Hardest decision will be when to sell on the meteoric rise (IF and when they announce something more substantial)

EU - Estimates suggest there are around 80,000–150,000 people living with idiopathic pulmonary fibrosis (IPF) in the EU, though prevalence varies by country and is often underdiagnosed. Prevalence rate: ~3–9 per 100,000.

USA - The Pulmonary Fibrosis Foundation estimates over 250,000 people are living with pulmonary fibrosis in the US, with around 30,000–40,000 new cases diagnosed annually. IPF specifically affects around 100,000–150,000 people.

The current standard of care includes pirfenidone (Esbriet) and nintedanib (Ofev).

Ofev (Boehringer Ingelheim) Global sales > €2.7 billion annually

Esbriet (Roche/Genentech) Generated ~$1.2 billion globally before Roche discontinued its standalone development in 2023.

Combined, the global IPF treatment market is valued at ~$3.5–4 billion per year, expected to grow significantly with aging populations and broader diagnosis rates.

Sterling flying

CHF holding is currently worth around £530,000

Market cap £1.1M and only 67M free float

This can really move on the right news!

Https://money.tmx.com/quote/SAG/news/5562091086898318/CEOCAs_Inside_the_Boardroom_Sterling_Metals_Hits_4_Football_Fields_of_Copper_Near_Surface

1,000,000 shares purchase, tells me there's going to be news tomorrow

Significance of the ODD Confirmation

Regulatory Advantages

The ODD provides Nuformix with 10 years of market exclusivity in the European Union upon approval, along with benefits such as protocol assistance, fee reductions, and potential access to EU grants.

Therapeutic Innovation

NXP002 is a novel inhaled formulation of tranilast, targeting Idiopathic Pulmonary Fibrosis (IPF), a rare and fatal lung disease with limited treatment options. Delivering tranilast via inhalation aims to enhance efficacy and reduce systemic side effects compared to existing oral therapies. 

Market Potential

The IPF market is projected to grow to $8.8 billion by 2027. Current standard treatments, such as OFEV and Esbriet, have significant side effects leading to high discontinuation rates. NXP002’s inhaled approach could address these limitations, offering a competitive advantage. 

Intellectual Property Strength

Nuformix holds multiple patents for NXP002, including substance of matter and method of use patents granted in major markets like the US, Europe, and Japan. This robust IP portfolio enhances the asset’s commercial viability. 

Strategic Positioning

With the ODD in place, Nuformix is better positioned to attract licensing partners and investors, facilitating further development and potential commercialization of NXP002. 

In summary, the EMA’s confirmation of ODD for NXP002 not only validates Nuformix’s innovative approach to treating IPF but also provides strategic advantages that could accelerate the drug’s development and market entry.

Would be amazed if there’s no RNS

Always see RNS’s when there’s “media speculation” etc. as this is an official announcement and emails have been exchanged and leaked then surely this has to be officially reported via RNS one way or another

Not many chances you get to be in for the RNS!

Prospectus can't be far away

they know what they needed £1M for

I expect it's pending final approval from the lawyers / autdior etc etc.

Once it drops, we might see 2p + once again ... hopefully many multiples, but like to stay grounded these days

Then again, anything that mentions fintech / AI can 100 bag lol

Could this finally be the run to 2p + ?

Investment Advisory Board

The Investment Advisory Board (“IAB”) has been established to support the identification and evaluation of acquisition targets, with a focus on the transformative potential of artificial intelligence in financial services. It comprises Simon Retter as Chair, with Richard Samuel and David Brown being the other members.

Free float is only c 60m shares atm

Float 61.39M

% held by insiders 5.12%

% held by institutions 20.11%

Ignore the super rampers

Expecting results before Friday! Could see some interest building early this week, keeping an eye on large buys which would be a good indication.. as always lol

Financial freedom solutions on companies house

May 20th

Notification of Jonathan Amrani as a person with significant control on 19 May 2025

For what it’s worth

Have requested LSE to delete is, as I'm not sure how to do this myself, weirdly can't find any options! Thanks for commenting on the current situation, as MediMan said, lots of speculation around and excitement about what comes next here at FPP with someone like David Brown on the board!

Friday Retirement Rethink: Something Big Is Coming

What if the real retirement revolution… doesn’t look like a pension at all?

What if the answer to:

• rising cost of living,

• housing insecurity,

• and legacy loss…

…isn’t buried in a policy paper or investment return,

but hiding in plain sight — in your own front room?

We’ve spent years building products for pots.

But maybe it’s time to build something for people.

Something is coming.

It won’t just tweak the system — it will ask if we’ve been solving the wrong problem all along.

Asset-rich. Cash-poor. Forgotten. No longer.

You’ll know it when you see it.

Watch this space.

#RetirementRethink #NextChapter #Decumulation #HousingWealth #FreedomWallet #AssetRichCashPoor #FinancialWellbeing #ComingSoon

https://www.linkedin.com/posts/davidbrownhi55_retirementrethink-nextchapter-decumulation-activity-7331596960451215360-PsEQ?utm_source=share&utm_medium=member_ios&rcm=ACoAAAn35gQBSkiTYH0WWfUWsp4fmcd_f3rBtWc

Thanks, makes perfect sense

KEY FOR ME IS THIS SENTANCE "Financial Position: The company raised £1.25 million in equity in February and secured a £511,000 R&D tax credit in May 2025, extending its financial runway to at least mid-2026."

Fiinu is poised to pursue revenue generation in 2025, leveraging its product readiness, licensing momentum, and solid financial foundation. The company's focus on serving digitally underserved SMEs and financial institutions across Europe aligns with its vision to enhance liquidity and customer engagement through innovative solutions.

While past challenges have necessitated significant changes, Fiinu's current trajectory suggests a positive direction, contingent on successful execution of its strategic initiatives and market adoption of its offerings.

Key Highlights:

Operational Restructuring: Fiinu transitioned to a leaner, tech-focused model, reducing its monthly burn rate from £600,000 to £45,000.

Investegate

Strategic Partnerships: In January 2025, Fiinu signed non-binding Heads of Terms with an independent UK bank to white-label its Plugin Overdraft® solution. Discussions with other institutions are ongoing, indicating growing market interest.

Financial Position: The company raised £1.25 million in equity in February and secured a £511,000 R&D tax credit in May 2025, extending its financial runway to at least mid-2026.

Governance and Leadership: A positive board effectiveness review and key leadership appointments, including a new Executive Director and CFO in March 2025, underscore Fiinu's commitment to strong

Probably nothing, but another potential AI Business for the RTO / IPO?

David Brown is positioned at the intersection of tech and early-stage innovation, now apparently focused on AI aligning well with Mindspire's positioning. and is linked to both FPP and Mindspire’s narrative. This is often how RTOs begin... via common personnel laying groundwork.

Our man Eliot from Financial Freedom

https://www.linkedin.com/posts/eliot-frazier_i-couldnt-be-more-delighted-to-announce-activity-7328039028711198722-WZqi?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAn35gQBSkiTYH0WWfUWsp4fmcd_f3rBtWc

"David Brown - Financial Freedom in Retirement

"Congrats Eliot! 🎉"

Eliot Frazier - Chief Product and Technology Officer at MindSpire | Start-up Advisor

Cheers David! It's great to have you as a collaborator, friend and mentor..."

https://mindspire.co.uk/

https://www.linkedin.com/posts/janeollis_so-excited-to-announce-that-we-have-raised-activity-7325872302397579264-MBeU?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAn35gQBSkiTYH0WWfUWsp4fmcd_f3rBtWc

"Today, I’m proud to share that MindSpire has raised £850,000 to launch SONA™, a medical-grade wearable that helps people regulate stress, sharpen focus, and recover faster. It’s powered by NeuroSphere™, our adaptive AI platform that personalises every session to your life, goals, and state of mind. We call it neural toning and we think it’s the future of brain and nervous system health."

"MindSpire is about more than tech, it’s about giving people the tools to take back control of their lives. If you’re building in mental health, performance, longevity, or precision care, I’d love to connect.

And if you’re an investor looking for serious traction, a differentiated product, and a founder who won’t stop, I’m a good bet."